Swiss Re and Cancer Epidemiology: Shaping the Future of Life and Health Insurance

Estimated Reading Time: 6 minutes

Cancer continues to be one of the most significant global health challenges, with profound implications for both public health and the life and health insurance industries. Swiss Re, a global reinsurance leader, has conducted extensive research into cancer epidemiology, using data-driven insights to understand evolving trends, risk factors, and their impact on insurance. Their findings offer critical guidance for insurers adapting underwriting practices, product design, and pricing strategies in response to the shifting cancer landscape.[1]

Have you signed up to our weekly job alerts on Actuary List? We post 50 new handpicked jobs every week that match your expertise. To ensure you don’t miss out, sign up here. Here are a few examples of new jobs this week:

Rising Incidence and Evolving Demographics

Swiss Re’s analysis confirms a steady global rise in cancer incidence, driven by aging populations, environmental exposures, and lifestyle shifts. While cancer rates remain high in developed countries, emerging markets are seeing accelerated increases due to urbanization, dietary changes, and rising tobacco use.

Notably, certain cancers traditionally associated with older adults such as breast, kidney, pancreatic, uterine, and colorectal cancers are now increasingly diagnosed in adults under 50. This trend, particularly linked to obesity, is reshaping how insurers assess risks in younger age groups.

Medical Advances and the Paradox of Early Detection

Swiss Re highlights the dual-edged nature of medical progress. Advances in early detection and treatment have significantly improved survival rates for cancers like breast, prostate, and colorectal. For insurers, this means more policyholders living longer post-diagnosis shifting the burden from mortality to critical illness and disability claims.

At the same time, better screening inflates short-term incidence rates by identifying subclinical or early-stage cases. Insurers must recalibrate assumptions around claim frequency and duration to reflect this new reality.

The Role of Genomics and Predictive Analytics

Genetic insights are revolutionizing cancer risk assessment. Swiss Re emphasizes the potential of integrating polygenic risk scores (PRS) and family history into actuarial models where regulations allow. However, they caution against over-reliance on genetics alone, advocating for a holistic view that incorporates lifestyle and environmental risk factors.

This shift opens the door to more personalized underwriting, risk stratification, and prevention-linked insurance offerings.

Cancers of Growing Insurance Relevance

Swiss Re’s epidemiological breakdown identifies several cancers with increasing relevance for insurers:

Lung cancer remains a leading concern, particularly in regions with rising pollution or tobacco use.

Melanoma is surging in sunny climates and often affects younger, insured populations.

Hematological cancers (e.g., leukemia and lymphoma) are increasingly diagnosed, with survivorship improved by novel therapies resulting in prolonged care and income protection needs.

Tracking cancer subtypes and treatment innovations is critical to aligning claims assumptions with emerging patterns.

Regional Disparities and Product Customization

Swiss Re’s data reveals stark regional disparities in cancer outcomes, often tied to socioeconomic status and healthcare access. In lower-income regions, late diagnoses and limited treatment contribute to higher mortality.

Insurers operating across geographies should tailor offerings to local realities for example, by including travel-for-treatment coverage, tele-oncology access, or localized wellness riders. Education campaigns and preventive benefits can also mitigate long-term claim risks.

Rethinking Product Design for a Changing Disease

With cancer increasingly managed as a chronic condition, Swiss Re urges insurers to go beyond traditional lump-sum critical illness models. Instead, they recommend:

Tiered benefits based on cancer stage, recurrence, and survivorship

Income protection and rehabilitation support for long-term recovery

Cancer-specific plans and wellness-linked life policies, with premium flexibility tied to screening compliance

These innovations reflect a shift from one-time crisis coverage to ongoing support.

Actuarial Considerations in a Dynamic Risk Landscape

Swiss Re challenges actuaries to move beyond static morbidity assumptions. The dynamic nature of cancer incidence, treatment costs, and survival outcomes demands continuous model updates.

They advocate for incorporating machine learning techniques and leveraging real-world data such as cancer registries and electronic health records to forecast claim patterns. Special attention should be paid to the unpredictable financial impact of emerging treatments like immunotherapy.

Behavioral and Environmental Risk Insights

Cancer epidemiology cannot be separated from its behavioral and environmental roots. Swiss Re’s data shows strong links between cancer rates and modifiable risk factors like smoking, alcohol use, poor diet, inactivity, and carcinogen exposure.

Insurers can take a preventive approach by offering:

1. Wellness programs

2. Behavior-linked premium incentives

3. Wearables and digital health partnerships

4. Dynamic health scoring

5. Such initiatives reduce risk exposure while promoting healthier policyholder behavior.

6. Long COVID and Cancer: An Emerging Concern

Swiss Re flags the pandemic’s indirect impact on cancer claims. COVID-related disruptions to screenings and healthcare access may lead to a surge in advanced-stage diagnoses in the coming years, particularly in regions that faced prolonged lockdowns.

Insurers should stress test their models and adjust short-term reserves accordingly. Moreover, early research suggests that long COVID may influence immune function in ways that affect cancer vulnerability an area requiring close monitoring and interdisciplinary collaboration.

Survivorship: Redefining the Claims Lifecycle

With more people surviving cancer for decades, Swiss Re underscores the need to move away from single payout claim models. Survivors often require:

1. Ongoing healthcare support

2. Mental health services

3. Occupational rehabilitation

4. Partial return-to-work programs

Insurers must reconceptualize what constitutes a “claim event,” embracing multi-phase benefits and survivor-centric coverage structures.

Gender-Specific and Pediatric Insights

Swiss Re’s data shows significant variations by gender and age:

1. Breast cancer remains the most common cancer among women, with outcomes heavily dependent on screening availability.

2. Prostate cancer shows inconsistent survival trends, especially in lower-resource countries due to underdiagnosis.

3. Pediatric cancers, though rare, have profound long-term effects. Insurers should design child-focused products that include family income support, education continuity, and coverage for treatment-related late effects.

Ethics, Regulation, and Responsible Innovation

Swiss Re highlights the ethical responsibility of insurers using sensitive health data. They promote transparency, fairness, and regulatory alignment especially when incorporating genetic and behavioral data into underwriting.

They also emphasize that product innovation should serve public health goals. Insurers that support early detection, equitable access, and inclusive coverage can improve both risk outcomes and their market reputation.

The Road Ahead

Swiss Re’s deep dive into cancer epidemiology offers a forward-looking blueprint for insurers facing a rapidly evolving landscape. Insurers must pair data-driven strategies with empathetic, customer-focused design. By embracing flexibility, innovation, and preventive engagement, the insurance industry can better manage cancer-related risks and support policyholders through every stage of the cancer journey.

[1] https://www.swissre.com/reinsurance/insights/reducing-cancer-risk-metabolic-health.html#chapter-Recent-trends-in-cancer-epidemiology-what-is-early-onset-cancer-